Sanofi eyes 2022 filing for haemophilia drug fitusiran, despite safety issueSanofi’s much anticipated drug for both haemophilia A and B – fitusiran – could be filed in 2022 Share XSanofi eyes 2022 filing for haemophilia drug fitusiran, despite safety issuehttps://pharmaphorum.com/news/sanofi-eyes-2022-filing-for-haemophilia-drug-fitusiran-despite-safety-issue/
Scotland opens door to Translarna for Duchenne muscular dystrophyA disparity in UK access to a medicine for Duchenne muscular dystrophy (DMD) has been addressed, after Scotland Share XScotland opens door to Translarna for Duchenne muscular dystrophyhttps://pharmaphorum.com/news/scotland-opens-door-to-translarna-for-duchenne-muscular-dystrophy/
Sanofi licences in potential oral IL-17 drug from UK’s C4X DiscoverySanofi has licensed a potential inflammatory diseases drug from Manchester University spin-off C4X Discovery Holdings in a deal Share XSanofi licences in potential oral IL-17 drug from UK’s C4X Discoveryhttps://pharmaphorum.com/news/sanofi-licences-in-potential-oral-il-17-drug-from-uks-c4x-discovery/
Sanofi’s Sarclisa gains new US multiple myeloma indicationThe FDA has approved Sanofi’s Sarclisa (isatuximab) in combination with a new chemotherapy regimen for advanced multiple myeloma, Share XSanofi’s Sarclisa gains new US multiple myeloma indicationhttps://pharmaphorum.com/news/sanofis-sarclisa-gains-new-us-multiple-myeloma-indication/
GSK and Medicago’s plant-based COVID shot heads into phase 3At the start of the pandemic GlaxoSmithKline made its vaccine booster tech available looking for collaborations with other Share XGSK and Medicago’s plant-based COVID shot heads into phase 3https://pharmaphorum.com/news/gsk-and-medicagos-plant-based-covid-shot-heads-into-phase-3/
Sanofi, Regeneron prep filings for Libtayo in cervical cancerSanofi and Regeneron’s checkpoint inhibitor Libtayo has become the first immunotherapy to improve survival when used as a Share XSanofi, Regeneron prep filings for Libtayo in cervical cancerhttps://pharmaphorum.com/news/sanofi-regeneron-prep-filings-for-libtayo-in-cervical-cancer/
Sanofi/Translate start clinical trial of mRNA COVID shotSanofi and Translate BIO have begun a clinical trial of their potential mRNA COVID-19 shot, as the French Share XSanofi/Translate start clinical trial of mRNA COVID shothttps://pharmaphorum.com/news/sanofi-translate-start-clinical-trial-of-mrna-covid-shot/
Lilly’s Olumiant is first JAK drug backed by NICE for eczemaEli Lilly’s JAK inhibitor Olumiant has become the first drug in the JAK inhibitor class to be recommended Share XLilly’s Olumiant is first JAK drug backed by NICE for eczemahttps://pharmaphorum.com/news/lillys-olumiant-is-first-jak-drug-backed-by-nice-for-eczema/
Sanofi’s immunotherapy Libtayo gets FDA approval in first line lung cancerSanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated Share XSanofi’s immunotherapy Libtayo gets FDA approval in first line lung cancerhttps://pharmaphorum.com/news/sanofis-immunotherapy-libtayo-gets-fda-not-in-first-line-lung-cancer/
